Pet Cancer Therapeutics Market Size, Share, Growth Report, 2034

Pet Cancer Therapeutics Market: Industry Perspective

The global pet cancer therapeutics market size was worth around USD 4.78 billion in 2024 and is predicted to grow to around USD 12.06 billion by 2034 with a compound annual growth rate (CAGR) of roughly 9.7% between 2025 and 2034. The report analyzes the global pet cancer therapeutics market's drivers, restraints/challenges, and the effect they have on the demand during the projection period. In addition, the report explores emerging opportunities in the pet cancer therapeutics industry.

Request Free Sample

Pet Cancer Therapeutics Market: Overview

Pet cancer therapeutics is a new anti-cancer medicine that has the capacity to reduce the negative impact of cancer tissues. In addition to this, pet cancer therapeutics encompasses combination therapy as well as monotherapy. The current research activities mainly focus on the proliferation of new anti-cancer medicines for enhancing efficiency and minimizing treatment side effects.

Key Insights

• As per the analysis shared by our research analyst, the global pet cancer therapeutics market is estimated to grow annually at a CAGR of around 9.7% over the forecast period (2025-2034).
• Regarding revenue, the global pet cancer therapeutics market size was valued at around USD 4.78 billion in 2024 and is projected to reach USD 12.06 billion by 2034.
• The pet cancer therapeutics market is projected to grow at a significant rate due to increasing pet ownership, rising awareness of veterinary oncology, and advancements in targeted therapies and diagnostics.
• Based on Therapy Type, the Chemotherapy segment is expected to lead the global market.
• On the basis of Species, the Dogs segment is growing at a high rate and will continue to dominate the global market.
• Based on the Cancer Type, the Mast cell cancer segment is projected to swipe the largest market share.
• By End-user, the Veterinary Hospitals segment is expected to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Pet Cancer Therapeutics Market: Growth Factors

Rise in the occurrence of cancer in pets will proliferate the growth of the market across the globe

The growing trend of adopting pets like cats & dogs across the globe will promote the expansion of the pet cancer therapeutics market over the forecast timeline. An increase in the occurrence of pet cancer in developed nations will proliferate the global market growth in the years to come. Additionally, a surge in the pet population in countries like the U.S., UK, and Germany will culminate in humongous market demand over the estimated timespan.

Furthermore, a rise in awareness about pet ailments, along with a rise in the tendency towards spending on pet care as well as treatment of pets, will accelerate the growth of the market globally over the forecast period. Additionally, the rise in various kinds of cancers in dogs & cats and the surge in the funding of research activities pertaining to cancer therapy in canines & cats will prompt business growth over the span of the next few years. New product launches will contribute significantly to the expansion of the market in the upcoming years. For instance, in March 2023, Novartis declared that the newly launched Novartis Pluvicto™, a targeted radioligand therapy for prostate cancer, received approval from the U.S. FDA.

Pet Cancer Therapeutics Market: Restraints

Less availability of veterinary doctors can restrict the global industry expansion

Low availability of veterinary oncologists along with adverse effects caused due to pet cancer treatment can put the brakes on the global pet cancer therapeutics industry surge. High treatment costs can put up a huge hurdle in the growth path of the industry across the globe.

Pet Cancer Therapeutics Market: Opportunities

Surge in the unmet medical requirements to open new growth avenues for the global market

Rise in the unmet medical needs and growing potential of pet cancer-treating drugs will open new growth opportunities for the global pet cancer therapeutics market. Apart from this, a rise in the allocation of funds for pet cancer treatment research activities will promote the growth of the market in the coming years.

Pet Cancer Therapeutics Market: Challenges

Government objection to the use of high drug doses in treating pets suffering from cancer can prove a huge challenge for the global industry expansion

Government restrictions on the high dosage of medicines for treating cancer in pets, along with a need for approval of the pet cancer therapies from state authorities, can prove to be a big challenge for the global pet cancer therapeutics industry.

Request Free Sample

Pet Cancer Therapeutics Market: Segmentation Analysis

The global pet cancer therapeutics market is segmented based on therapy type, species, cancer type, end-user, and region.

Based on Therapy Type, the global pet cancer therapeutics market is divided into chemotherapy, targeted therapy, immunotherapy, and radiation therapy.

On the basis of Species, the global pet cancer therapeutics market is bifurcated into dogs, cats, and others. Moreover, the dogs segment, which dominated the segment in 2024, is predicted to dominate the global market share in the upcoming years. The segmental surge over the predicted timespan can be due to a rise in the occurrence of cancer in dogs due to inbreeding.

By Cancer Type, the global pet cancer therapeutics market is split into lymphoma, mast cell cancer, melanoma, mammary & skin cancer, and others. Moreover, the mast cell cancer segment, which accumulated a huge share of the global industry in 2024, is slated to lead the global industry over the projected timespan. The segmental growth over the assessment timeline can be subject to a rise in the occurrence of mast cell cancers in pets.   

In terms of End-user, the global pet cancer therapeutics market is categorized into veterinary hospitals, veterinary clinics, and research institutes.  

Pet Cancer Therapeutics Market: Report Scope

Pet Cancer Therapeutics Market: Regional Analysis

North American market is anticipated to retain its numero uno position over the expected timeline

The growth of the pet cancer therapeutics market in the North American sub-continent over the forecast timeline is due to the huge presence of reputed industry participants in countries like the U.S. Additionally, a large-scale product penetration as well as product innovation to effectively treat various kinds of pet cancers will elevate the market growth over the estimated timeline. Apart from this, a rise in spending on veterinary care of pets by pet owners and supportive government guidelines related to research on pet cancer in countries such as the U.S. will proliferate the regional market size.

Asia-Pacific pet cancer therapeutics industry is set to register the fastest CAGR in the next couple of years due to the presence of key players in the developing countries of the region.

Pet Cancer Therapeutics Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the pet cancer therapeutics market on a global and regional basis.

The global pet cancer therapeutics market is dominated by players like:

• Karyopharm Therapeutics Inc.
• Zoetis
• Oasmia Pharmaceuticals AB
• Zenoaq
• AB Science
• Aratana Therapeutics Inc.
• Rhizen Pharmaceuticals SA
• Morphogenesis Inc.
• Boehringer Ingelheim International GmbH
• Regeneus Ltd.
• VetDC Inc.

The global pet cancer therapeutics market is segmented as follows:

By Therapy Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Radiation Therapy

By Species

• Dogs
• Cats
• Others

By Cancer Type

• Lymphoma
• Mast Cell Cancer
• Melanoma
• Mammary & Skin Cancer
• Others

By End-user

• Veterinary Hospitals
• Veterinary Clinics
• Research Institutes

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa